Hailshadow/iStock via Getty Images Royalty Pharma (RPRX) will provide $100M in funding to Zealand Pharma (ZLDPF) in exchange for a royalty for rusfertide (PTG-300), its candidate from the rare blood disease polycythemia vera. Terms call for Royalty to have rights to a 1% royalty on Source link Like this:Like Loading… Related Post navigation IEA and OPEC split on global oil demand estimates as Strait of Hormuz closure drags
